Therefore, in the event of a negative result we should move to the next test in sequence. For the majority of people with ...

Asthma attacks and chronic obstructive ... The injection treat flare-ups called "eosinophilic exacerbation" and involve symptoms including wheezing, coughing and chest tightness due to ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

or leukotriene modifier/theophylline in order to control symptoms. Eosinophils are the major inflammatory cells which are considered a biomarker for asthma and eosinophilic inflammation correlates ...

Eosinophilic inflammation plays a role in at least half of asthma and one-third of COPD flare-ups. For these people, targeting eosinophils when symptoms worsen is a promising strategy.

A new injection, benralizumab, outperforms traditional steroids in treating asthma and COPD attacks, reducing treatment ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

Scientists say this is the first new way of treating the attacks in 50 years despite 3.8 million deaths across the world ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulm ...

Episodes of worsening respiratory symptoms in asthma or COPD, driven by high levels of eosinophils (white blood cells) that cause inflammation in the airways. Laboratory-engineered molecules that can ...

Benralizumab can be used at a lower dose to manage symptoms in people with eosinophilic asthma. But the finding that a higher dose injection during an attack leads to better outcomes is significant.